查看完整行情页>>

|

货币单位:美元(USD)

Beacon Therapeutics (USA), Inc. (agtc)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
David Jacobs Currently, David Jacobs holds the position of Senior VP-Clinical Research & Medical Affairs at Applied Genetic Technologies Corp.
Susan Schneider Currently, Susan Schneider is Chief Medical Officer of Applied Genetic Technologies Corp. In the past she was Chief Medical Officer for Oxurion NV, Senior Vice President-Clinical Development at Jixing Pharmaceutical Technology (Shanghai) Co. Ltd., Director-Clinical & Scientific Affairs at Bausch & Lomb, Inc., Medical Director for Genentech, Inc., Chief Medical Officer at Santen, Inc., Senior Director-Ophthalmology at GlaxoSmithKline LLC, Principal at New York Eye & Ear Infirmary and Principal at The University of Cincinnati College of Medicine. She received an undergraduate degree from the University of Pennsylvania.
Abraham Scaria Presently, Abraham Scaria holds the position of Chief Scientific Officer of Beacon Therapeutics (USA), Inc. Dr. Scaria previously was Vice President & Head-Ophthalmology at Casebia Therapeutics LLC, Chief Scientific Officer at IVERIC bio, Inc., Senior Scientific Director-Gene Therapy at Genzyme Corp. and Head-Gene Therapy Research at Sanofi Corp. He received a doctorate from The Indiana University School of Medicine and a graduate degree from the University of Mumbai.
Nadia Waheed Presently, Nadia Waheed holds the position of Chief Medical Officer at Gyroscope Therapeutics Holdings Plc and Chief Medical Officer for Beacon Therapeutics (USA), Inc. Dr. Waheed received a graduate degree from Harvard T.H. Chan School of Public Health and a doctorate from Aga Khan University.
Gerald A. Reynolds Currently, Gerald A. Reynolds is Treasurer for Beacon Therapeutics (USA), Inc.
Sarah C. DiSalvatore Sarah C. DiSalvatore holds the position of Vice President-Clinical Operations at Applied Genetic Technologies Corp. In the past she held the position of Associate Vice President-Clinical Operations at Rocket Pharmaceuticals, Inc.
Matthew Feinsod Founder of Imagen Biotech, Inc., Matthew Feinsod presently is Executive VP-Global Strategy & Development at Applied Genetic Technologies Corp. Dr. Feinsod is also on the board of World Eye Mission. In the past he was Chief Medical Officer of Imagen Biotech, Inc., Senior VP-Strategy & Product Development at Eyetech Pharmaceuticals, Inc., Member-Institutional Review Board at The George Washington University Hospital and Medical Officer at US Food & Drug Administration. He received a doctorate from George Washington University and an undergraduate degree from The Wharton School of the University of Pennsylvania.
David A. Fellows David A. Fellows is an American businessperson who has been at the head of 5 different companies and currently is Chairman for Oxular Ltd., Chairman for Terns Pharmaceuticals, Inc. and Chief Executive Officer & Secretary at Beacon Therapeutics (USA), Inc. Mr. Fellows is also on the board of 5 other companies. Mr. Fellows previously was Chief Executive Officer & Director at Nightstar Therapeutics Ltd., Managing Director at Allergan Ltd., Vice President for Allergan, Inc. and Vice President of Johnson & Johnson Vision Care, Inc. David A. Fellows received an undergraduate degree from Butler University.
Stephen W. Potter Stephen W. Potter is Chief Business Officer & Vice President at Applied Genetic Technologies Corp. He previously held the position of SVP-Operations & Corporate Development at Osiris Therapeutics, Inc., Senior VP-Corporate & Business Development at Genzyme Corp., Executive Vice President for NeoStem, Inc. and Executive Vice President of Caladrius Biosciences, Inc. Mr. Potter received an undergraduate degree from the University of Massachusetts and an MBA from Harvard Business School.
Scott E. Koenig Founder of MacroGenics, Inc., Scott E. Koenig currently holds the position of Chairman at Applied Genetic Technologies Corp. and President, Chief Executive Officer & Director at MacroGenics, Inc. Dr. Koenig is also on the board of Biotechnology Innovation Organization, GlycoMimetics, Inc. and The International Biomedical Research Alliance and Member of Cornell University Council. Dr. Koenig previously held the position of Senior Vice President-Research at Medimmune, Inc., Principal at National Institute of Allergy & Infectious Diseases, Chairman of Children's Research Institute, Inc., Principal at National Institutes of Health and Trustee-Advisory Board at Cornell University. He received a doctorate and an undergraduate degree from Cornell University and a doctorate from The University of Texas Health Science Center at Houston.
Jonathan I. Lieber Presently, Jonathan I. Lieber is Chief Financial Officer of Applied Genetic Technologies Corp. Mr. Lieber is also on the board of Salarius Pharmaceuticals, Inc. and Member-Audit Committee at Atrius Health, Inc. In the past Mr. Lieber held the position of Chief Financial Officer at Danforth Advisors LLC, President & Chief Financial Officer of Organovo Holdings, Inc., Chief Financial Officer & Treasurer for Repligen Corp., Chief Financial Officer & Senior Vice President for Metamark Genetics, Inc., Chief Financial Officer, Treasurer & Senior VP of Altus Pharmaceuticals, Inc., Chief Financial Officer & Treasurer for Xcellerex, Inc., Chief Financial Officer of Histogenics Corp., Chief Financial Officer for Checkmate Pharmaceuticals, Inc., Vice President at Cowen & Co. LLC and Member-Health Care & High Yield Group at Salomon Brothers, Inc. Jonathan I. Lieber received an undergraduate degree from Boston University and an MBA from The Leonard N Stern School of Business.
Susan B. Washer Currently, Susan B. Washer is President, Chief Executive Officer & Director at Applied Genetic Technologies Corp. Ms. Washer is also on the board of 7 other companies. In her past career she held the position of President & Chief Executive Officer of Scenic Productions, Inc., Principal at Eli Lilly & Co. and Principal at Abbott Laboratories (Pakistan) Ltd. Ms. Washer received an undergraduate degree from Michigan State University, an MBA from Warrington College of Business Administration and an MBA from the University of Florida.
Anne M. VanLent Founder of Technology Compass Group LLC and AMV Advisors, Anne M. VanLent currently occupies the position of President of AMV Advisors. She is also on the board of 6 other companies. In her past career Ms. VanLent occupied the position of Chief Financial Officer for Neurogenics, Inc., Principal at Technology Compass Group LLC, Chief Financial Officer & Senior Vice President at The Liposome Co., Inc., Chief Financial Officer & Executive Vice President of Barrier Therapeutics, Inc. and Executive Vice President-Portfolio Management at Sarnoff Corp. She received an undergraduate degree from Mount Holyoke College.
Edward M. Hurwitz Edward M. Hurwitz founded Precision BioVentures LLC and Viewpoint Therapeutics, Inc. Presently, Mr. Hurwitz is Chairman at Rekindle Therapeutics, Inc., Chairman at Biointervene, Inc., Chief Financial Officer for Turmeric Acquisition Corp., Managing Director at Precision BioVentures LLC, Managing Director at MPM Capital Inc and Chairman of Viewpoint Therapeutics, Inc. Mr. Hurwitz is also Manager for Alta Embarcadero Biopharma Partners III LLC and on the board of 6 other companies. In the past he held the position of Director at Alta Partners Management Corp. and Chief Financial Officer & Senior Vice President of Affymetrix, Inc. He received an undergraduate degree from Cornell University, an MBA from Haas School of Business and a graduate degree from Berkeley Law University of California.
Ivana Magovcevic-Liebisch Currently, Ivana Magovcevic-Liebisch holds the position of Chairman of Absci Corp. and President, Chief Executive Officer & Director at Vigil Neuroscience, Inc. She is also on the board of 5 other companies. She previously held the position of Senior VP & Head-Global Business Development at Teva Pharmaceutical Industries Ltd., Chief Business Officer & Executive Vice President at Ipsen SA, Executive VP, Chief Strategy & Development Officer at Axcella Health, Inc., Chief Operating Officer & Executive Vice President for Dyax Corp. and Director-Intellectual Property & Patent Counsel at Transkaryotic Therapies, Inc. Dr. Magovcevic-Liebisch received a doctorate from Harvard University, a graduate degree from Suffolk University Law School and an undergraduate degree from Wheaton College (Illinois).
James Rosen James Rosen is on the board of Applied Genetic Technologies Corp. and Director-Public Health Foundation at Unc Gillings School of Global Public Health. Mr. Rosen previously occupied the position of President & Chief Executive Officer at Artizan Biosciences, Inc., Partner at Intersouth Partners and Partner at Intersouth Associates VI LLC (a subsidiary of Intersouth Partners), Equity Research Analyst at Brean Murray & Co., Principal at The Robert Wood Johnson Foundation, Deputy Director-Venture Investing at Bill & Melinda Gates Foundation Trust and Principal at Duke University Medical Center. Mr. Rosen received an undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School.
Arnold Lewis Oronsky Arnold Lewis Oronsky holds the position of Chairman of EpicentRx, Inc. He is also on the board of 9 other companies. In the past he held the position of Chairman of Dynavax Technologies Corp., General Partner of InterWest Partners LLC, Vice President-Discovery Research at Lederle Laboratories, Vice President-Discovery Research at Wyeth Holdings LLC, Head-Inflammation, Allergy & Immunology Research at Ciba-Geigy Corp. and Head-Inflammation, Allergy & Immunology at Ciba-Geigy Pharmaceuticals. Dr. Oronsky received an undergraduate degree from New York University and a doctorate from Columbia University College of Physicians & Surgeons.